International GMP Enforcement — Q3 2026: Pattern Analysis Across 14…

Regulatory Event

Between April 14 and July 13, 2026, XGene tracked 14 international Good Manufacturing Practice (GMP) enforcement actions across the European Medicines Agency (EMA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) networks: 13 EudraGMDP non-compliance records covering 12 unique manufacturing companies, plus one MHRA Statement of Non-Compliance with GMP. The WHO Prequalification Programme recorded zero manufacturer suspensions or Notices of Concern for finished pharmaceutical products or active pharmaceutical ingredients in the same window — a genuine “none found” result rather than a search gap. That count is itself a data point: a quarter with 14 published actions and zero WHO suspensions signals that, for now, enforcement pressure in the international human-pharmaceutical space is concentrated in the EMA and MHRA networks rather than distributed evenly across all three. Product type mix skews toward solid oral dose and sterile parenteral manufacturing, with a distinct biologics/biosimilar case and a small veterinary-medicine sub-cluster sitting outside the core human-pharmaceutical trend this quarter.

Data integrity and pharmaceutical quality system documentation failures are the clearest recurring theme among the cases with published narrative detail. Geno Pharmaceuticals’ MHRA statement explicitly cites the generation and retention of unreliable GMP records, compromising data integrity, as one of five critical deficiencies, alongside a failure to maintain a comprehensively designed Pharmaceutical Quality System (PQS). Zenzi Pharmaceutical Industries’ FDA Warning Letter centers on a records-access refusal under Section 704(a)(4) of the FD&C Act — a data-integrity-adjacent failure, since the underlying problem is an inability to substantiate manufacturing records on demand. Bio-Thera Solutions’ EU finding, categorized as a deviation management deficiency rather than classic data integrity, is a related quality-system-documentation failure. Across the three cases with public narrative detail this quarter, documentation and quality-system traceability failures outweigh classic technical or sterility findings. Sterile and parenteral injectable manufacturing forms a distinct sub-cluster within the broader dataset: two separate Swiss Parenterals units in Ahmedabad and Navesta Pharmaceuticals’ sterile injectable plant in Sri Lanka together account for three of the 13 EMA records, a concentration that deserves separate monitoring even though none of the three met this quarter’s threshold for an individual article.

What the Record Documents

Of the 12 unique EMA- and MHRA-flagged companies this quarter, six trace to the Indian subcontinent: Geno Pharmaceuticals, Zenzi Pharmaceutical Industries, Cadchem Laboratories, both flagged Swiss Parenterals units, and Navesta Pharmaceuticals in Sri Lanka — exactly half of this quarter’s international company count. China accounts for two (Sichuan New Hawk Biotechnology and Bio-Thera Solutions), and the EU itself accounts for two (Laboratorios Eurisko in Spain and Technophage in Portugal). A veterinary-scope cluster in the Netherlands (Veyx-Pharma, Produlab Pharma) and one US-based veterinary site (Intervet Inc.) round out the dataset but sit outside the human-pharmaceutical enforcement trend. South Asia is the clear geographic concentration point for this quarter’s human-pharmaceutical enforcement activity. This concentration is not, on its own, evidence that manufacturing quality in the region is systematically weaker than elsewhere; it may equally reflect the sheer volume of contract manufacturing capacity based in South Asia relative to other regions, combined with the inspection cadence EU and UK authorities currently apply there. Both explanations point toward the same practical conclusion for supply chain teams: verification effort should be weighted toward this geography this quarter, without treating it as the only geography worth watching.

The Zenzi Pharmaceutical Industries case is this quarter’s clearest cross-authority convergence signal. FDA flagged the site over a records-access refusal in February 2025; roughly fifteen months later, Malta’s competent authority, acting within the EMA network, independently found the identical site non-compliant with EU GMP. Neither authority appears to have relied on the other’s findings to reach its own conclusion. That pattern — a site failing one regulator’s documentation standard and later failing another’s, without coordinated triggering — suggests data integrity and records traceability are a persistent, cross-border risk category rather than an artifact of any single authority’s inspection style. It is also the case that a site failing on documentation grounds in one jurisdiction does not automatically fail identically elsewhere; the Bio-Thera Solutions finding shows a related but distinct documentation-adjacent category — deviation management — can surface independently of a classic data integrity citation, which argues for verifying specific deficiency categories rather than treating every finding as interchangeable.

Technical and Quality Context

The most analytically interesting pattern this quarter is not a shared finding; it is a publication gap. MHRA issued exactly one non-compliance statement in the past 90 days, and only six in the entire life of its public MHRA-GMDP database, while the EMA/EudraGMDP network published 13 statements in the identical window across multiple member-state authorities. That is not evidence that UK-inspected sites are cleaner than EU-inspected ones. It more likely reflects a structural difference in enforcement and publication architecture: MHRA is a single national authority applying a high, often recall-triggered threshold — in this quarter’s case, a threshold crossed only after three Class II recalls — while EMA’s non-compliance statements are compiled from many independent national competent authorities, each with its own inspection cadence and disclosure practice, and often published with less narrative detail than MHRA provides. For companies building supplier risk assessments, the practical lesson is that the absence of a published non-compliance statement from a given authority is not, by itself, strong evidence of compliance; it may simply reflect that authority’s inspection cadence or publication threshold. EMA’s own three-year GMP Inspectors Working Group programme, alongside ongoing stakeholder consultations covering documentation, computerised systems, and a proposed new annex addressing data-governance-adjacent expectations, suggests this emphasis on documentation and traceability is not incidental to this quarter’s cases but reflects where the inspectorate’s own attention is already headed for the next several review cycles.

For pharmaceutical companies with internationally distributed supply chains, this quarter’s data supports three concrete priorities heading into the next inspection cycle: treat documentation and quality-system traceability as the highest-probability finding category across every jurisdiction, not only FDA’s; verify supplier GMP status directly against each relevant authority’s own database — EudraGMDP, MHRA-GMDP, and FDA’s establishment records — rather than relying on the absence of a public finding as a proxy for compliance; and pay particular attention to sites in South Asia given this quarter’s concentration, without assuming sites elsewhere carry lower risk, since publication gaps in other networks may simply be masking comparable issues. None of these three priorities requires waiting for a formal enforcement notice to act on; each can be operationalized now, using the public records already reviewed for this report.

Decision Relevance

XGene Consulting compiles this quarterly international enforcement intelligence specifically so clients don’t have to reconstruct it themselves from three separate regulator databases with three different disclosure standards. If your supplier qualification program still treats “no Warning Letter found” as sufficient evidence of a clean international supply chain, this quarter’s data suggests otherwise. Contact XGene Consulting to build a cross-jurisdictional supplier verification program ahead of your next inspection cycle.